Hutchison Pharmaceuticals re-launched the Hong Kong Stock Exchange IPO, Fruquintinib revenue exceeded 200 million

According to Reuters' IFR report, Hutchison Medicine plans to start an IPO on the Hong Kong Stock Exchange as early as the first half of 2021, and plans to raise US$500 million.

As early as April 15, 2019, Hutchison China Pharmaceuticals submitted an A1 form to apply for listing on the main board of the Hong Kong Stock Exchange.

According to the latest financial report released by Hutchison Medicine, its total revenue in 2020 will be US$228 million (US$204.

In addition, the company's own oncology drug commercialization team has expanded to more than 420 employees, with sales costs of US$188.

Hutchison Pharmaceuticals began rolling submission of new drug marketing applications for Sofatinib to the US FDA in December 2020 to treat pancreatic and non-pancreatic neuroendocrine tumors; it is planned to be completed in the first half of 2021.

Among its listed drugs, in addition to fruquintinib and sofatinib, in 2020 the company also submitted a new drug application for saivotinib for the treatment of lung cancer.

Up to now, 30 non-profit biotechnology companies have successfully IPO on the Hong Kong Stock Exchange.